A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers
Authors
Keywords
Phosphorylation, Gastrointestinal tract, Gastric cancer, Cancer detection and diagnosis, Ascites, Breast cancer, Prognosis, Surgical and invasive medical procedures
Journal
PLoS One
Volume 8, Issue 1, Pages e54644
Publisher
Public Library of Science (PLoS)
Online
2013-01-26
DOI
10.1371/journal.pone.0054644
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study
- (2017) M. P. Jhawer et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.
- (2017) S. Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
- (2011) R. Ghosh et al. CANCER RESEARCH
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells
- (2011) H. Xu et al. CLINICAL CANCER RESEARCH
- Molecular Classification of Gastric Cancer: A New Paradigm
- (2011) M. A. Shah et al. CLINICAL CANCER RESEARCH
- Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome
- (2011) Maria D. Begnami et al. JOURNAL OF CLINICAL ONCOLOGY
- Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients
- (2011) Phillip Kim et al. Proteome Science
- Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells
- (2010) F. Hochgrafe et al. CANCER RESEARCH
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
- (2010) Simona Corso et al. Molecular Cancer
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer
- (2009) Chia Huey Ooi et al. PLoS Genetics
- High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer
- (2008) M. Hayashi et al. CLINICAL CANCER RESEARCH
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy
- (2008) Jeffrey A Engelman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
- (2008) Soonmyung Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started